Replies to post #246912 on Biotech Values

[TwoNE1]

AQST closed down -21%

It was likely profit-taking after the significant rise of AQST, and there may be an expectation that AQST will take the opportunity to raise capital.

[DewDiligence]

SPRY -55% on CRL for intranasal epinephrine:

https://finance.yahoo.com/news/fda-issues-complete-response-letter-024900831.html

FDA now requests repeat-dose study be completed prior to neffy approval as opposed to previously agreed-upon post-marketing requirement.